Senzime AB (SEZI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Senzime AB (SEZI) has a cash flow conversion efficiency ratio of -0.091x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-27.69 Million ≈ $-2.98 Million USD) by net assets (Skr304.46 Million ≈ $32.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Senzime AB - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Senzime AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Senzime AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Senzime AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Senzime AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yew Lee Pacific Group Berhad
KLSE:0248
|
0.009x |
|
Cheng Fwa Industrial Ltd
TWO:5426
|
0.017x |
|
Ispire Technology Inc. Common Stock
NASDAQ:ISPR
|
0.518x |
|
Farmsco
KO:036580
|
-0.006x |
|
Highland Copper Company Inc.
V:HI
|
-0.087x |
|
Ibkimyoung Co. Ltd
KQ:339950
|
0.107x |
|
Progress-Werk Oberkirch AG
XETRA:PWO
|
0.024x |
|
Space Shuttle Hi-Tech Co Ltd
TW:2440
|
-0.127x |
Annual Cash Flow Conversion Efficiency for Senzime AB (2006–2025)
The table below shows the annual cash flow conversion efficiency of Senzime AB from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see SEZI company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr304.46 Million ≈ $32.76 Million |
Skr-109.10 Million ≈ $-11.74 Million |
-0.358x | -16.98% |
| 2024-12-31 | Skr345.86 Million ≈ $37.22 Million |
Skr-105.94 Million ≈ $-11.40 Million |
-0.306x | -0.97% |
| 2023-12-31 | Skr375.48 Million ≈ $40.41 Million |
Skr-113.91 Million ≈ $-12.26 Million |
-0.303x | +41.91% |
| 2022-12-31 | Skr261.90 Million ≈ $28.18 Million |
Skr-136.78 Million ≈ $-14.72 Million |
-0.522x | +3.31% |
| 2021-12-31 | Skr150.58 Million ≈ $16.20 Million |
Skr-81.33 Million ≈ $-8.75 Million |
-0.540x | -225.94% |
| 2020-12-31 | Skr231.35 Million ≈ $24.90 Million |
Skr-38.34 Million ≈ $-4.13 Million |
-0.166x | +0.04% |
| 2019-12-31 | Skr163.69 Million ≈ $17.62 Million |
Skr-27.14 Million ≈ $-2.92 Million |
-0.166x | -56.49% |
| 2018-12-31 | Skr167.41 Million ≈ $18.02 Million |
Skr-17.73 Million ≈ $-1.91 Million |
-0.106x | -21.04% |
| 2017-12-31 | Skr140.46 Million ≈ $15.12 Million |
Skr-12.29 Million ≈ $-1.32 Million |
-0.088x | -15.36% |
| 2016-12-31 | Skr131.87 Million ≈ $14.19 Million |
Skr-10.00 Million ≈ $-1.08 Million |
-0.076x | +45.81% |
| 2015-12-31 | Skr45.81 Million ≈ $4.93 Million |
Skr-6.41 Million ≈ $-690.18K |
-0.140x | -60.40% |
| 2014-12-31 | Skr44.08 Million ≈ $4.74 Million |
Skr-3.85 Million ≈ $-414.05K |
-0.087x | +39.78% |
| 2013-12-31 | Skr37.46 Million ≈ $4.03 Million |
Skr-5.43 Million ≈ $-584.31K |
-0.145x | +23.55% |
| 2012-12-31 | Skr31.99 Million ≈ $3.44 Million |
Skr-6.06 Million ≈ $-652.57K |
-0.190x | -170.80% |
| 2011-12-31 | Skr27.87 Million ≈ $3.00 Million |
Skr-1.95 Million ≈ $-209.94K |
-0.070x | +27.67% |
| 2010-12-31 | Skr21.90 Million ≈ $2.36 Million |
Skr-2.12 Million ≈ $-228.10K |
-0.097x | -0.30% |
| 2009-12-31 | Skr16.61 Million ≈ $1.79 Million |
Skr-1.60 Million ≈ $-172.54K |
-0.096x | -664.63% |
| 2006-12-31 | Skr7.55 Million ≈ $812.29K |
Skr129.00K ≈ $13.88K |
0.017x | -- |
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive … Read more